FCRL5/FcRH5/IRTA2 Antibody [Allophycocyanin]

Mouse splenocytes were stained with Rat Anti-Mouse B220/CD45R Fluorescein-conjugated Monoclonal Antibody (Catalog # FAB1217F) and either (A) Sheep Anti-Mouse FCRL5 APC-conjugated Antigen Affinity-purified Polyclonal Antibody (Catalog # FAB6757A) or (B) Normal Sheep IgG Allophycocyanin Control (Catalog # IC016A). View our protocol for Staining Membrane-associated Proteins.

• Reactivity: Mu
• Applications: Flow
• Clonality: Polyclonal
• Host: Sheep
• Conjugate: Allophycocyanin

FCRL5/FcRH5/IRTA2 Antibody [Allophycocyanin] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse FCRL5/FcRH3
  Gln27-Ala496 (predicted)
  Accession # NP_899045
• Specificity: Detects mouse FCRL5/FcRH3 in direct ELISAs. In direct ELISAs, less than 1% cross-reactivity with recombinant human FCRL5 is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Sheep
• Gene: FCRL5
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 10 uL/10^6 cells

Packaging, Storage & Formulations

• Storage: Store the unopened product at 2 - 8° C. Do not use past expiration date. Protect from light.
• Buffer: Supplied in a saline solution containing BSA and Sodium Azide.
• Preservative: Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for FCRL5/FcRH5/IRTA2 Antibody [Allophycocyanin]

• BXMAS1
• BXMAS1MGC119592
• CD307
• CD307e antigen
• CD307e
• DKFZp667E2019
• DKFZp667F216
• Fc receptor homolog 5
• Fc receptor-like 5
• Fc receptor-like protein 5
• FcRH5
• FCRH5MGC119593
• FCRL5
• FcR-like protein 5
• FLJ00333
• FLJ00397
• IFGP5
• Immune receptor translocation-associated protein 2
• immunoglobulin superfamily receptor translocation associated 2 (IRTA2)
• IRTA2
• IRTA2MGC119590
• PRO820

Background

Fc Receptor-Like 5 (FCRL5), also known as FcRH3 (FcRH5 in human), IRTA2, and CD307e, is a 90‑95 kDa member of the FCRL family of proteins whose amino acid (aa) sequence is reminiscent of that for classical Fc receptors. FCLR molecules are type 1 transmembrane proteins that contain from three to nine immunoglobulin-like domains. They are differentially expressed within the B cell lineage, and can either promote or inhibit B cell proliferation and activation (1, 2, 3). Mature mouse FCRL5 consists of a 470 aa extracellular domain (ECD), a 21 aa transmembrane segment, and a 79 aa cytoplasmic region. The ECD contains five Ig-like domains, while the cytoplasmic region possesses one ITAM-like motif and one immunotyrosine inhibitory motif (ITIM) (1, 3, 4). There are two major alleles for FCLR5 in mouse. The first was just described, and is found in BALB/c plus NZB mouse strains. The second is found in C57BL/6 mice, and differs by eleven scattered aa in the ECD. This creates one additional N-linked glycosylation site, and increases the SDS‑PAGE MW by 5 kDa (3). Alternate splicing of mouse FCRL5 generates at least one additional isoform that lacks the first Ig-like domain (aa 3‑90 of the mature molecule) (4). Human FCRL5, by contrast, contains up to nine Ig-like domains in a highly variable ECD, and over common regions, mouse and human FCRL5 share 49% aa sequence identity. CRL5 expression is restricted to mature B lineage cells in lymphoid tissues and blood, and is particularly noted to be expressed on T‑independent marginal zone and B1 B cells (3-8). Its ligation inhibits signaling through the B cell antigen receptor (9). Epstein-Barr virus transformation of B cells induces the up‑regulation of surface FCRL5 by a direct effect of its EBNA2 protein on FCRL5 gene transcription (10). FCRL5 on B cells functions as a receptor for the orthopoxvirus MHC class I-like protein OMCP (11). And based on the literature and R&D Systems testing, both mouse and human FCRL5 will bind to purified IgG with high affinity (5). In human, the FCRL5 gene maps to the 1q21 chromosomal locus, a common site of rearrangements in B cell malignancies. Notably, the FCRL5 protein is preferentially expressed in cell lines with 1q21 abnormalities, and is up‑regulated on tumor cells in some types of B cell malignancies (5, 7, 12‑14). In addition, soluble FCRL5 is elevated in the serum of many B cell leukemia patients (13, 15).

1. Davis, R.S. (2007) Annu. Rev. Immunol. 25:525.
2. Maltais, L.J. et al. (2006) Nat. Immunol. 7:431.
3. Won, W-J. et al. (2006) J. Immunol. 177:6815.
4. Davis, R.S. et al. (2004) Int. Immunol. 16:1343.
5. Hatzivassiliou, G. et al. (2001) Immunity 14:277.
6. Miller, I. et al. (2002) Blood 99:2662.
7. Polson, A.G. et al. (2006) Int. Immunol. 18:1363.
8. Vidal-Laliena, M. et al. (2005) Cell. Immunol. 236:6.
9. Haga, C.L. et al. (2007) Proc. Natl. Acad. Sci. 104:9770.
10. Mohan, J. et al. (2006) Blood 107:4433.
11. Campbell, J.A. et al. (2010) J. Immunol. 185:28.
12. Ise, T. et al. (2005) Clin. Cancer Res. 11:87.
13. Ise, T. et al. (2007) Leukemia 21:169.
14. Kazemi, T. et al. (2009) Cancer Immunol. Immunother. 58:989.
15. Ise, T. et al. (2006) Clin. Chem. Lab. Med. 44:594.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: FCRL5
• Uniprot:
  • NP_899045()